TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03051152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Description: Gastrectomy with extended lymph node dissection
Study: NCT01161212

Intervention type: OTHER
Group type: OTHER
Intervention: Physical education sessions
Description: 3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions

Intervention type: OTHER
Group type: OTHER
Intervention: Physical education sessions
Description: 1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
Study: NCT04056234

Intervention type: PROCEDURE
Intervention: Joint puncture
Description: Patient requiring joint puncture for diagnostic or therapeutic reasons.

Intervention type: PROCEDURE
Intervention: Joint puncture
Description: Patient requiring joint puncture for diagnostic or therapeutic reasons.
Study: NCT03279120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV/LNG IVR
Description: Used for 90 days (Continuous or Interrupted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV/LNG IVR
Description: Used for 90 days (Continuous or Interrupted)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Used for 90 days (Continuous or Interrupted)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Used for 90 days (Continuous or Interrupted)
Study: NCT00659945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant plus Ondansetron
Description: Aprepitant plus Ondansetron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron plus placebo
Description: Ondansetron plus placebo
Study: NCT02866721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10\^6, 3 x 10\^6 or 5 x 10\^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation.
Study: NCT03532048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Papás Saludables, Niños Saludables Program
Description: Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Papás Saludables, Niños Saludables Wait-list Control
Description: The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
Study: NCT05417373

Intervention type: OTHER
Intervention: calculated radscore
Description: The development cohort is case_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
Study: NCT02708576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM313
Study: NCT05937061

Intervention type: OTHER
Intervention: Influence of food allergy on growth (intervention groups)
Description: Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.

Intervention type: OTHER
Intervention: Influence of food allergy on growth (intervention groups)
Description: Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.
Study: NCT02769754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Hemopatch will be apply once the standard surgical hemostasis is achieved.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No additional treatment will be applied after performing the usual surgical hemostasis.
Study: NCT01420328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vytorin
Description: Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment for 6 weeks
Study: NCT00842959

Intervention type: DEVICE
Group type: OTHER
Intervention: Invent ZO
Description: monofocal aspheric IOL for implantation into capsular bag

Intervention type: DEVICE
Group type: OTHER
Intervention: XL Stabi ZO
Description: monofocal aspheric IOL for implantation into capsular bag
Study: NCT02903602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sharing Histories training method for CHW
Description: Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard training method for CHW
Description: Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
Study: NCT02708576

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05937061

Intervention type: OTHER
Intervention: Influence of food allergy on growth (intervention groups)
Description: Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.
Study: NCT01462240

Intervention type: DEVICE
Intervention: LPS Flex Porous Femoral Components
Description: Porous femoral components in total knee arthroplasty
Study: NCT02780180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
Study: NCT01040624

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: < 15% risk of + LN
Description: Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
Study: NCT03771300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: This program is structured around two central elements, mindfulness and compassion. The sessions combine theory and practice components, using a methodology which priorities the reflection and debate among the students. Regarding theory component, mindfulness and compassion concepts will be set out over the length of the program, in addition to others related to time management, stress, anxiety and the balance between personal life and academic/work life. The practical component of the program consists of mindfulness and self-compassion formal and informal practices under the guidance of a specialized instructor.
Study: NCT02788110

Intervention type: OTHER
Group type: OTHER
Intervention: Noninvasive neurally adjusted ventilatory assist (NIV NAVA)
Description: Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.

Intervention type: OTHER
Group type: OTHER
Intervention: Noninvasive neurally adjusted ventilatory assist (NIV NAVA)
Description: Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
Study: NCT01040624

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: > 15% risk of + LN
Description: Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
Study: NCT04498975

Intervention type: OTHER
Intervention: Rurality; Ethnicity; Exercise; Hopelessness
Description: Observational study exploring rurality, ethnicity, exercise and hopelessness patterns cross-sectionally and longitudinally
Study: NCT05428306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)
Description: Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
Study: NCT03863665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci
Description: Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
Study: NCT01019070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-650032
Description: Capsules, Oral, 200 mg, BID, 7 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-650032
Description: Capsules, Oral, 200 mg, BID, 7 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-650032
Description: Capsules, Oral, 200 mg, BID, 7 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-650032
Description: Capsules, Oral, 200 mg, BID, 7 Days
Study: NCT03410524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone Solution
Description: 200 mg of Simethicone in 3 mL of Simethicone Solution Formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 3 mL of water as placebo added to the bowel preparation
Study: NCT03292380

Intervention type: OTHER
Intervention: No intervention was included
Study: NCT00676013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integra
Description: Grafting using the Commercial product Integra as a skin substitute over full thickness burn following excision.
Study: NCT05428306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)
Description: A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)
Description: A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
Study: NCT00676013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AlloDerm
Description: Grafting using the commercial product AlloDerm as a skin substitute

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Homograft
Description: Grafting using homograft as a skin substitute

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autograft
Description: grafting using patients own skin from a separate donor site
Study: NCT04215640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfidelity (MIFI) catheter
Description: Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.
Study: NCT02015312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate (EGCG)
Description: Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months
Study: NCT04215640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ablation catheter
Description: Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.
Study: NCT00858624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
Study: NCT02487095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan (in combination with VX-970 (M6620) administered by intravenous (IV) Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan (in combination with VX-970 (M6620) administered by intravenous (IV) Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-970 (M6620)
Description: VX-970 (M6620 (in combination with Topotecan) administered by intravenous (IV) Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
Study: NCT03771300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness condition complemented by VR
Description: The VR is comprised of a Samsung VR goggles, a Samsung Galaxy S6 phone and optional headphones.~In this condition, the instructor is the same as previously but the implementation of VR will be carried out by a psychologist specially trained for the application of these VR scenarios. Prior to the VR use, the psychologist will make sure about the participants´ health.
Study: NCT02487095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-970 (M6620)
Description: VX-970 (M6620 (in combination with Topotecan) administered by intravenous (IV) Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
Study: NCT03115762

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKB1202
Study: NCT00965250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-12
Description: 20 mg/kg intravenously once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-12
Description: 20 mg/kg intravenously once every three weeks
Study: NCT01987102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [6R] 5,10-methylenetetrahydrofolate (arfolitixorin)
Description: The enrolled patients will be treated according to the MAP schedule and will receive the study drug \[6R\] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate® dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.
Study: NCT02788110

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Description: Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae.
Study: NCT01987102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [6R] 5,10-methylenetetrahydrofolate (arfolitixorin)
Description: The enrolled patients will be treated according to the MAP schedule and will receive the study drug \[6R\] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate® dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.
Study: NCT00592488

Intervention type: DRUG
Group type: OTHER
Intervention: Acetyl-L-Carnitine
Description: Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
Study: NCT02132819

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Withholding feeds
Description: At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: feeding during transfusion
Description: The feeding process will be continued during the transfusion
Study: NCT04806074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Evidence-based food-related national and international guidelines were (i) specifically arranged considering the Food Literacy Wheel (Rosas et al., 2021) and personalised materials contained these guidelines were designed, (ii) matched with tailored behaviour change techniques (BCT Taxonomy v1, by Michie et al., XXXX) that indicated how to develop/implement each competence/behaviour, and (iii) digitally delivered weekly. Psychological variables of the Health Action Process Approach model (HAPA; Schwarzer, 2008) were integrated in the intervention, to study potential food literacy's psychological determinants. Weekly introduction videos featuring the lead psychologist were made available. Participants' groups in WhatsApp were built to incentive experience-sharing. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparison Group
Description: Food-related guidelines were delivered in a single moment in the first week of the intervention, on their original format and referring their original source (national's and international's entities websites). There was not a thematic for each specific week. No weekly introduction videos or WhatsApp groups existed in this condition. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
Study: NCT05065788

Intervention type: OTHER
Intervention: data collection
Description: data collection